This transcript has been edited for clarity.
Continuous glucose monitoring (CGM), especially flash CGM, is often prescribed to patients with diabetes, especially in those treated with basal-bolus insulin therapy.
We did a study to evaluate acute hospitalization for diabetes events in patients with type 2 diabetes treated with basal-only insulin therapy. With this Social Security database, we were able to individualize 6000 patients with type 2 diabetes treated with basal-only insulin therapy.
We made the comparison of the number of days of hospitalization 1 year before flash glucose monitoring prescription, and 1 and 2 years after this prescription. We observed a huge reduction of hospitalization for ketoacidosis, around 60%, and a 40% reduction in hospitalization for severe hypoglycemia 1 year after flash glucose monitoring. At 2 years after, we observed a 70% reduction of ketoacidosis, suggesting that this improvement is sustainable 2 years after.
We were able to evaluate the evolution of our population according to whether the prescription was given by a general healthcare practitioner or a specialist, and we observed the same reduction of hospitalization whichever the prescriber. We were also able to evaluate the evolution of the treatment of the patients. At 1 year and 2 years after, we observed a huge increase in patients treated with basal-bolus insulin therapy, suggesting that flash glucose monitoring is able to fight against clinical inertia.
This study strongly suggests that flash glucose monitoring is a tool able to improve clinical event hospitalization for ketoacidosis or severe hypoglycemia in patients living with type 2 diabetes treated with basal-only insulin therapy, whether it was a prescription from a general healthcare practitioner or a specialist. This improvement could help the physician fight against clinical inertia.
Medscape Diabetes © 2022
Cite this: Flash CGM Sustainably Reduces Acute Hospitalizations in T2D - Medscape - Oct 21, 2022.